Gen-Probe Licenses Tumor Cell Detection Technology from AdnaGen for Diagnostic Tests

NEW YORK, Jan. 4 (GenomeWeb News) -- Gen-Probe has licensed a tumor cell detection technology from AdnaGen of Germany, the San Diego-based company said this week.

The technology allows for the detection of rare, circulating tumor cells by first isolating cancerous cells from healthy cells using an immunoassay followed by measuring gene expression in these cells. 

Under the terms of the agreement, Gen-Probe obtains exclusive access to AdnaGen's technology for molecular diagnostic tests for prostate and bladder cancer. Gen-Probe will pay AdnaGen license fees of $1 million, as well as $750,000 in the first quarter of 2006 or when AdnaGen's patent issues, whichever happens later. Gen-Probe may also pay AdnaGen three milestones totaling an additional $2.25 million. In addition, AdnaGen will receive royalties on sales of products developed using its technology.

Gen-Probe also obtains options to exclusively license the technology for kidney, ovarian, and cervical cancer. Also, the company has a three-year right of first refusal for using the technology for breats, colon, and lung cacner tests.